Expression of Beta Defensin 2 in Experimental Pulmonary Tuberculosis: Tentative Approach for Vaccine Development

Archives of Medical Research

Volumn 43, Issue 4, 2012, Pages 324-328

  Rivas Santiago, Bruno ^a   Cervantes Villagrana, Alberto ^a,b   Sada, Eduardo ^c   Hernández Pando, Rogelio ^d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d National Institute for Medical Sciences and Nutrition Salvador Zubiran   (Mexico)

Author keywords

defensin; Dendritic cells; Tuberculosis

Indexed keywords

BCG VACCINE; BETA DEFENSIN 2;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; DRUG DESIGN; FEMALE; GENE EXPRESSION; GENE LOCATION; GENETIC ANALYSIS; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MALE; MEDIASTINUM LYMPH NODE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TH1 CELL;

ADAPTIVE IMMUNITY; ANIMALS; BETA-DEFENSINS; CROSSES, GENETIC; DENDRITIC CELLS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; IMMUNITY, CELLULAR; IMMUNOENZYME TECHNIQUES; LATENT TUBERCULOSIS; LUNG; LYMPHATIC VESSELS; MALE; MEDIASTINUM; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; REAL-TIME POLYMERASE CHAIN REACTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TH1 CELLS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84864085729     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.06.005     Document Type: Article

References (20)

1. Lehrer R.I. Multispecific myeloid defensins. Curr Opin Hematol 2007, 14:16-21.
2. Durr M., Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun 2002, 70:6515-6517.
3. Biragyn A. Defensins-non-antibiotic use for vaccine development. Curr Protein Pept Sci 2005, 6:53-60.
4. Biragyn A., Surenhu M., Yang D., et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001, 167:6644-6653.
5. Aarbiou J., Verhoosel R.M., Van Wetering S., et al. Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am J Respir Cell Mol Biol 2004, 30:193-201.
6. Ginsburg I. Bactericidal cationic peptides can also function as bacteriolysis-inducing agents mimicking beta-lactam antibiotics? It is enigmatic why this concept is consistently disregarded. Med Hypotheses 2004, 62:367-374.
7. Biragyn A., Ruffini P.A., Leifer C.A., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298:1025-1029.
8. Biragyn A., Coscia M., Nagashima K., et al. Murine beta-defensin 2 promotes TLR-4/MyD88-mediated and NF-κB-dependent atypical death of APCs via activation of TNFR2. J Leukoc Biol 2008, 83:998-1008.
9. Moranta D., Regueiro V., March C., et al. Klebsiella pneumoniae capsule polysaccharide impedes the expression of beta-defensins by airway epithelial cells. Infect Immun 2010, 78:1135-1146.
10. Wu M., McClellan S.A., Barrett R.P., et al. Beta-defensin-2 promotes resistance against infection with P. aeruginosa. J Immunol 2009, 182:1609-1616.
11. Falzon D., Jaramillo E., Schünemann H.J., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
12. Rivas-Santiago B., Sada E., Tsutsumi V., et al. β-Defensin gene expression during the course of experimental tuberculosis infection. J Infect Dis 2006, 194:697-701.
13. Hernández-Pando R., Orozcoe H., Sampieri A., et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996, 89:26-33.
14. Arriaga A.K., Orozco E.H., Aguilar L.D., et al. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002, 128:229-237.
15. Sharma S., Verma I., Khuller G.K. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 2000, 16:112-117.
16. Sharma S., Verma I., Khuller G.K. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 2001, 45:639-640.
17. Rivas-Santiago B., Schwander S.K., Sarabia C., et al. Human β-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun 2005, 73:4505-4511.
18. Rivas-Santiago C.E., Rivas-Santiago B., León D.A., et al. Induction of beta-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin Exp Immunol 2011, 164:80-89.
19. García-Romo G.S., Pedroza-González A., Aguilar-León D., et al. Airways infection with virulent Mycobacterium tuberculosis delays the influx of dendritic cells and the expression of costimulatory molecules in mediastinal lymph nodes. Immunology 2004, 112:661-668.
20. Verbsky J.W. Therapeutic use of T regulatory cells. Curr Opin Rheumatol 2007, 19:252-258.